

Antonella Sistigu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3606179/publications.pdf>

Version: 2024-02-01

41
papers

8,864
citations

257101

24
h-index

301761

39
g-index

41
all docs

41
docs citations

41
times ranked

14728
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. <i>Cell Death and Differentiation</i> , 2018, 25, 486-541.	5.0	4,036
2	Cancer cellâ€™s autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014, 20, 1301-1309.	15.2	823
3	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
4	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
5	An Immunosurveillance Mechanism Controls Cancer Cell Ploidy. <i>Science</i> , 2012, 337, 1678-1684.	6.0	367
6	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015, 350, 972-978.	6.0	367
7	Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis. <i>Cancer Research</i> , 2011, 71, 768-778.	0.4	304
8	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. <i>Seminars in Immunopathology</i> , 2011, 33, 369-383.	2.8	265
9	IL-33 restricts tumor growth and inhibits pulmonary metastasis in melanoma-bearing mice through eosinophils. <i>Oncolmmunology</i> , 2017, 6, e1317420.	2.1	137
10	CCL2/CCR2-Dependent Recruitment of Functional Antigen-Presenting Cells into Tumors upon Chemotherapy. <i>Cancer Research</i> , 2014, 74, 436-445.	0.4	118
11	Trial Watch: Targeting ATMâ€™s CHK2 and ATRâ€™s CHK1 pathways for anticancer therapy. <i>Molecular and Cellular Oncology</i> , 2015, 2, e1012976.	0.3	117
12	Type I IFNs Control Antigen Retention and Survival of CD8 ⁺ Dendritic Cells after Uptake of Tumor Apoptotic Cells Leading to Cross-Priming. <i>Journal of Immunology</i> , 2011, 186, 5142-5150.	0.4	110
13	Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. <i>Oncolmmunology</i> , 2017, 6, e1314424.	2.1	106
14	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017, 280, 165-174.	2.8	82
15	Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 351-358.	1.0	75
16	Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoediting. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 67-77.	3.2	71
17	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 396-416.	3.6	66
18	CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells. <i>Gut</i> , 2018, 67, 903-917.	6.1	64

#	ARTICLE	IF	CITATIONS
19	Tuning Cancer Fate: Tumor Microenvironment's Role in Cancer Stem Cell Quiescence and Reawakening. <i>Frontiers in Immunology</i> , 2020, 11, 2166.	2.2	60
20	IRF-8 Controls Melanoma Progression by Regulating the Cross Talk between Cancer and Immune Cells within the Tumor Microenvironment. <i>Neoplasia</i> , 2012, 14, 1223-IN43.	2.3	48
21	A multidisciplinary study using <i>in vivo</i> tumor models and microfluidic cell-on-chip approach to explore the cross-talk between cancer and immune cells. <i>Journal of Immunotoxicology</i> , 2014, 11, 337-346.	0.9	48
22	The Immune Privilege of Cancer Stem Cells: A Key to Understanding Tumor Immune Escape and Therapy Failure. <i>Cells</i> , 2021, 10, 2361.	1.8	36
23	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. <i>Cancer Immunology Research</i> , 2018, 6, 658-670.	1.6	34
24	Replication stress response in cancer stem cells as a target for chemotherapy. <i>Seminars in Cancer Biology</i> , 2018, 53, 31-41.	4.3	31
25	Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition. <i>Oncotarget</i> , 2016, 7, 885-901.	0.8	31
26	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. <i>Oncolimmunology</i> , 2015, 4, e988042.	2.1	27
27	The added value of type I interferons to cytotoxic treatments of cancer. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 89-97.	3.2	25
28	The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. <i>Biology</i> , 2021, 10, 856.	1.3	21
29	Macrophages Transmit Human Immunodeficiency Virus Type 1 Products to CD4-Negative Cells: Involvement of Matrix Metalloproteinase 9. <i>Journal of Virology</i> , 2007, 81, 9078-9087.	1.5	20
30	Trial watch “inhibiting PARP enzymes for anticancer therapy. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1053594.	0.3	19
31	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. <i>Cell Death and Differentiation</i> , 2021, 28, 2060-2082.	5.0	19
32	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. <i>Cells</i> , 2020, 9, 940.	1.8	8
33	The Targeting of MRE11 or RAD51 Sensitizes Colorectal Cancer Stem Cells to CHK1 Inhibition. <i>Cancers</i> , 2021, 13, 1957.	1.7	8
34	Human immunodeficiency virus type 1 (HIV-1) protease inhibitors block cell-to-cell HIV-1 endocytosis in dendritic cells. <i>Journal of General Virology</i> , 2009, 90, 2777-2787.	1.3	6
35	Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 471-486.	1.1	5
36	Microfluidic Co-Culture Models for Dissecting the Immune Response in <i>in vitro</i> Tumor Microenvironments. <i>Journal of Visualized Experiments</i> , 2021, , .	0.2	5

#	ARTICLE	IF	CITATIONS
37	LTX-315, CAPtivating immunity with necrosis. <i>Cell Cycle</i> , 2016, 15, 1176-1177.	1.3	3
38	Assessment of IFN- β and granzyme-B production by in in vitro technology. <i>Methods in Enzymology</i> , 2020, 631, 391-414.	0.4	3
39	Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer?. <i>Biology</i> , 2021, 10, 913.	1.3	2
40	Cytofluorometric assessment of dendritic cell-mediated uptake of cancer cell apoptotic bodies. <i>Methods in Enzymology</i> , 2020, 632, 39-54.	0.4	1
41	Molecular Mechanisms of Immunogenic Cell Death. , 2017, , .		0